Nanjing Advanced Biotechnology and Life Sciences Research Institute is supported by the Key Laboratory of Microbial Physiology and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, and mainly researches core key technologies and industrialization in advanced biotechnology and life sciences.
Research directions and features:
In advanced biotechnology, it mainly carries out research and application of novel biocatalyst development technologies based on metabolic engineering and synthetic biology, as well as advanced bioprocess engineering technologies, specifically including:
1. Research on modification and optimization technologies of metabolic engineering chassis cells
2. Research on technologies for efficient promotion of biosynthesis of target compounds by cofactor self-balancing systems
3. Development and application of integrated continuous biomanufacturing processes
4. Research on advanced fermentation and intelligent control technologies
5. Advanced biomanufacturing processes and applications
In the direction of life sciences, it mainly carries out research and evaluation of human biological organ functions (such as islet function) and metabolite research, series of new drug development and novel medical device development and their industrialization based on discovered targets and new targets, and regenerative medicine research and industrialization. Specifically including:
1. Islet function screening platform for new diabetes drug R&D;
2. Early diagnosis technologies for metabolic diseases;
3. R&D and translation of drugs for rare diseases;
4. R&D of advanced biotherapy methods based on "regenerative medicine" for severe complications of diabetes.
Existing achievements:
In the direction of advanced biotechnology: a series of highly efficient biological enzymes have been developed; sialic acid, lycopene, trehalose, glucosamine, etc. have been successfully developed, which can be used in pharmaceuticals, food, cosmetics, agriculture and other fields, and some products have leading industrialization technologies and have reached the global top three in scale; breakthrough progress has been made in the biofermentation processes of unsaturated fatty acids and various enzyme preparations; breakthroughs in lipid-lowering yeast fermentation technology and metabolic engineering, i.e., using genetically modified lipid-lowering yeast to convert waste biological oils and fats into various high value-added products; novel bioreactors have been designed and developed, breaking through and solving the problems of low efficiency and high cost of traditional stirred fermentation tanks in the biomanufacturing industry; industrialization of integrated continuous fermentation production technology, i.e., establishing a complete set of new continuous biomanufacturing processes integrating microbial growth, directed evolution, fermentation and product separation into a complete system.
In the direction of life sciences: in the field of amino acid-stimulated insulin secretion*, several entirely new mechanisms have been elucidated; it has been discovered that the green tea component EGCG can effectively treat abnormal insulin secretion caused by GDH mutations, and led the new drug R&D of GDH inhibitors; it has been discovered that GLP-1 receptor antagonists can treat abnormal insulin secretion caused by potassium channel mutations; the pathogenesis of 3 types of congenital hyperinsulinism has been elucidated, and drug R&D projects have been launched; participated in the drug R&D of glucokinase activators for the treatment of type 2 diabetes; established methods for metabolomics research of islet metabolism and constructed methods for high-throughput screening of diabetes drugs.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows